title: First oral thrombin inhibitor enters market: drug does not require clinicians to monitor INR.
authors.forename: Cheryl A
authors.initials: CA
authors.lastname: Thompson
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D000069604:Dabigatran; D016903:Drug Monitoring; D004617:Embolism / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D019934:International Normalized Ratio; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D020521:Stroke / Q000209:etiology / Q000517:prevention & control; D013917:Thrombin / Q000037:antagonists & inhibitors*
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D011725:Pyridines; D013917:Thrombin; D000069604:Dabigatran